Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

57.59 +1.78 (+3.20%)
Streaming Delayed Price Updated: 10:27 AM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
90 91 Next >
News headline image
What's going on in today's pre-market session: S&P500 movers ↗
Discover the top S&P500 movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Tesla To $303? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides ↗
Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups. 
Via Benzinga
News headline image
Bristol-Myers Squibb (BMY) Reports Earnings Tomorrow: What To Expect
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results tomorrow morning. Here’s what investors should know. 
Via StockStory
News headline image
Bristol Myers Squibb Stock Slides After-Hours As Schizophrenia Trial Misses Goal, But Retail's Buying The Dip ↗
A post-hoc analysis showed more pronounced effects among patients on risperidone compared to those on other antipsychotics, the company said. 
Via Stocktwits
Topics Intellectual Property
News headline image
Stay updated with the S&P500 stocks that are on the move in today's after-hours session. ↗
After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Beyond The Numbers: 7 Analysts Discuss Bristol-Myers Squibb Stock ↗
 
Via Benzinga
News headline image
Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test ↗
The company spent $14 billion to acquire the developer of this drug, Cobenfy. 
Via Investor's Business Daily
News headline image
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach ↗
FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use 
Via Benzinga
News headline image
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
From Bristol Myers Squibb
Via Business Wire
News headline image
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
News headline image
Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday? ↗
Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns. 
Via Benzinga
News headline image
Which S&P500 stocks are moving on Tuesday? ↗
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session. 
Via Chartmill
News headline image
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Curious about the S&P500 stocks that are gapping on Tuesday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It ↗
The companies are facing off with their heart drugs in a growing disease area. 
Via Investor's Business Daily
News headline image
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
From Bristol Myers Squibb
Via Business Wire
News headline image
These Large-Cap Stocks With China And EU Exposure Got Crushed In The One Of The Most Volatile Trading Week (Apr 7-Apr 11): Are These In Your Portfolio? ↗
Large-cap stocks, such as PDD, PBR, KMX, APTV, STLA, CRWV, BMY, Z, BABA, and YUMC, saw significant declines due to trade tensions and missed earnings. 
Via Benzinga
Topics World Trade
News headline image
Why BRISTOL-MYERS SQUIBB CO (NYSE:BMY) qualifies as a good dividend investing stock. ↗
Analyzing BRISTOL-MYERS SQUIBB CO (NYSE:BMY)'s Dividend Potential. 
Via Chartmill
News headline image
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight ↗
Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells. 
Via Benzinga
News headline image
3 Value Stocks in the Doghouse
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
News headline image
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
Via Benzinga
Topics Government World Trade
News headline image
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash ↗
Here's why the 90-day tariffs delay doesn't help pharmaceutical companies. 
Via Investor's Business Daily
Topics Government Stocks World Trade
News headline image
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success ↗
Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program. 
Via Benzinga
News headline image
Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
What's going on in today's session: S&P500 movers ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday. 
Via Chartmill
News headline image
These S&P500 stocks are gapping in today's session ↗
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
90 91 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.